Analgesia Clinical Trial
— PIEBOfficial title:
Programmed Intermittent Epidural Bolus (PIEB) Techniques for Labour Analgesia; Finding the Optimum Combination
Epidural Analgesia remains the most effective form of pain relief in labour. After initiating epidural analgesia, there are many epidural drug regimens that can be employed to maintain analgesia for the duration of labour using an epidural catheter. Due to recent advances in medical technology, new epidural pumps, which allow both patient controlled epidural analgesia boluses (PCEA, a common standard of care in many hospitals) and programmed intermittent epidural boluses (PIEB, automatic boluses given in addition to the PCEA bolus), are now available. In this randomized double-blind trial, we aim to evaluate the effects of different combinations of PIEB (epidural bolus volume) and PIEB (bolus volume and time interval) on labour patient-controlled epidural analgesia (PCEA) usage. In theory, the more effective the PIEB combination (the ideal drug volume and ideal time interval), the less PCEA boluses (extra epidural drug) will be used as well as less clinician boluses and less lower limb weakness (motor block) as assessed by the Bromage Score.
Status | Not yet recruiting |
Enrollment | 200 |
Est. completion date | April 30, 2024 |
Est. primary completion date | April 20, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Age 18 to 50 yrs - In active labour - ASA 2 patients (pregnant patients are considered to be ASA 2) - Singleton pregnancy - > 37 weeks gestation - Booking BMI 18 to 35 Exclusion Criteria: - BMI < 18 - BMI > 35 - Systemic opioids within the previous 6 hours - Presence of a fetal anomaly - Pre-eclampsia - Bleeding disorders (including coagulation disorders) - Recent spinal surgery - Spinal injury - Elevated intracranial pressure (ICP) - Neuraxial disorders of any description - Signs of local or systemic infection - Patient refusal for neuraxial analgesia |
Country | Name | City | State |
---|---|---|---|
Qatar | Hamad Medical Corporation (HMC) | Doha |
Lead Sponsor | Collaborator |
---|---|
Hamad Medical Corporation |
Qatar,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The volume of local anaesthetic mixture for breakthrough pain (PCEA + clinician bolus) + the Bromage Score | The (composite) primary outcome will identify the 2 best performing groups | From the siting of the epidural block to the delivery of the fetus (maximum 24 hrs) | |
Secondary | Pain score | Numeric Rating Scale (NRS). Patient self-reported pain scale. 0 (No Pain) to 10 (Worst possible pain) | From the siting of the epidural block to the delivery of the fetus (maximum 24 hrs) | |
Secondary | Total local anesthetic consumption | Initial Epidural Bolus + Total volume PIEB + Total volume PCEA + Clinician bolus volume | From the siting of the epidural block to the delivery of the fetus (maximum 24 hrs) | |
Secondary | Need for supplementary epidural analgesia | Total volume PCEA + Total volume clinician Bolus | From the siting of the epidural block to the delivery of the fetus (maximum 24 hrs) | |
Secondary | Bromage score (lower limb weakness score) | Bromage Score -1: Free movement of legs and feet, 2: Just able to flex knees, able to move feet, 3: Unable to flex knees, able to move feet, 4 :Unable to move legs or feet | From the siting of the epidural block to the delivery of the fetus (maximum 24 hrs) | |
Secondary | Type of delivery | Normal vaginal delivery, cesarean delivery, forceps and vacuum delivery | From the siting of the epidural block to the delivery of the fetus (maximum 24 hrs) | |
Secondary | Sensory block | Assessed with cold spray (ethyl chloride) | From the siting of the epidural block for 3 hours | |
Secondary | Fetal Outcome | Umbilical cord blood gases + Apgar scores | At the time of birth and 5 minutes after delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05534230 -
Dexmedetomidine for Pain Reduction in CABG
|
N/A | |
Recruiting |
NCT06275698 -
HONEY for the Treatment of POst-Tonsillectomy Pain
|
N/A | |
Recruiting |
NCT04436224 -
Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation
|
Phase 4 | |
Not yet recruiting |
NCT04548323 -
Hypoalgesic Effects of Walking and Running Imagined
|
||
Completed |
NCT06054945 -
Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
|
||
Completed |
NCT04394481 -
Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery
|
Phase 4 | |
Completed |
NCT04690647 -
The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement.
|
N/A | |
Completed |
NCT05034601 -
ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure
|
N/A | |
Completed |
NCT03740815 -
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
|
N/A | |
Recruiting |
NCT05454202 -
Assessment of the Interest of ANI in the Non-communicating Patient in Palliative Care
|
||
Recruiting |
NCT04554186 -
Serratus Anterior Plane Block Versus Thoracic Paravertebral Block.
|
N/A | |
Not yet recruiting |
NCT06393777 -
Effectiveness of Pre-administered Natural Sweet-tasting Solution (Honey) for Decreasing Pain of Needle Insertion
|
N/A | |
Suspended |
NCT04860635 -
Safety of F14 Following Total Knee Replacement
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04519463 -
The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing
|
Early Phase 1 | |
Completed |
NCT02916342 -
Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks
|
Phase 4 | |
Not yet recruiting |
NCT02549118 -
Tenoxicam for Intrapartum Analgesia
|
Phase 2 | |
Completed |
NCT03206554 -
Local Infiltration Analgesia in Total Knee Arthroplasty
|
Phase 2 | |
Not yet recruiting |
NCT02190760 -
Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block.
|
N/A | |
Completed |
NCT01789606 -
Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet
|
Phase 3 | |
Completed |
NCT01299584 -
ULTIVA Post Marketing Surveillance
|
N/A |